Catalog No.: PC-62511Not For Human Use, Lab Use Only.
CPI 203 (TEN 010, JQ-2, RG-6146, RO6870810) is a primary amide analog of (+)-JQ1and a BET bromodomain inhibitor that shows cytotoxicity against MCL cell lines with GI50 of 0.1-0.3 uM.
CPI 203 (TEN 010, JQ-2, RG-6146, RO6870810) is a primary amide analog of (+)-JQ1and a BET bromodomain inhibitor that shows cytotoxicity against MCL cell lines with GI50 of 0.1-0.3 uM.
CPI 203 synergizes the antitumor activity of lenalidomide in bortezomib-resistant mantle cell lymphoma.
CPI 203 also enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors, overcomes resistance to ABT-199 (Venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
